JP2025512735A5 - - Google Patents

Info

Publication number
JP2025512735A5
JP2025512735A5 JP2024554120A JP2024554120A JP2025512735A5 JP 2025512735 A5 JP2025512735 A5 JP 2025512735A5 JP 2024554120 A JP2024554120 A JP 2024554120A JP 2024554120 A JP2024554120 A JP 2024554120A JP 2025512735 A5 JP2025512735 A5 JP 2025512735A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
cdr
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512735A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064203 external-priority patent/WO2023173132A1/en
Publication of JP2025512735A publication Critical patent/JP2025512735A/ja
Publication of JP2025512735A5 publication Critical patent/JP2025512735A5/ja
Pending legal-status Critical Current

Links

JP2024554120A 2022-03-11 2023-03-11 Glp1ペプチド模倣体を含む抗glp1r抗体係留型薬物コンジュゲートおよびその使用 Pending JP2025512735A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263319175P 2022-03-11 2022-03-11
US63/319,175 2022-03-11
PCT/US2023/064203 WO2023173132A1 (en) 2022-03-11 2023-03-11 Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof

Publications (2)

Publication Number Publication Date
JP2025512735A JP2025512735A (ja) 2025-04-22
JP2025512735A5 true JP2025512735A5 (https=) 2026-03-16

Family

ID=85779020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554120A Pending JP2025512735A (ja) 2022-03-11 2023-03-11 Glp1ペプチド模倣体を含む抗glp1r抗体係留型薬物コンジュゲートおよびその使用

Country Status (9)

Country Link
US (1) US20230330254A1 (https=)
EP (1) EP4489855A1 (https=)
JP (1) JP2025512735A (https=)
KR (1) KR20240159847A (https=)
CN (1) CN119072335A (https=)
AU (1) AU2023231305A1 (https=)
CA (1) CA3243669A1 (https=)
MX (1) MX2024011099A (https=)
WO (1) WO2023173132A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024229138A1 (en) * 2023-02-27 2025-09-18 Regeneron Pharmaceuticals, Inc. Liquid phase peptide support synthesis of peptides and peptidomimetics
WO2024211135A2 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
US20250171516A1 (en) 2023-11-03 2025-05-29 Regeneron Pharmaceuticals, Inc. Peptide acids as a glp1r agonist and antibody-drug conjugates thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
FR2937972B1 (fr) 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
BR112014009070B1 (pt) 2011-10-14 2021-11-23 Medimmune Limited Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
WO2015015448A2 (en) 2013-07-31 2015-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
US9911931B2 (en) 2014-06-26 2018-03-06 Universal Display Corporation Organic electroluminescent materials and devices
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
IL313587A (en) * 2017-01-17 2024-08-01 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
KR20200007905A (ko) * 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
JP7702428B2 (ja) * 2020-05-12 2025-07-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗glp1rアンタゴニスト抗体およびその使用方法
CA3191304A1 (en) 2020-09-14 2022-03-17 Amy Han Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof

Similar Documents

Publication Publication Date Title
JP2025512735A5 (https=)
AU2016232839B2 (en) CD48 antibodies and conjugates thereof
JPWO2019240287A1 (ja) 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2026053628A (ja) 抗炎症剤に連結されたecm親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物
JP2021513844A (ja) グリピカン3抗体およびそのコンジュゲート
EP2486058A1 (en) Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
JP2021531825A5 (https=)
JP7605290B2 (ja) 化合物またはその塩、およびそれらにより得られる抗体
JP2019507580A5 (https=)
JP2019505166A5 (https=)
JP2024504923A5 (https=)
WO2019031615A1 (ja) ヘミアスタリン誘導体及びこれらの抗体薬物複合体
JP2025124732A (ja) 化合物またはその塩、およびそれらにより得られる抗体
CA3206543A1 (en) Antibody-drug conjugate and medical use thereof
WO2024213040A1 (zh) 抗ror1抗体及其药物偶联物
WO2019031614A1 (ja) ヘミアスタリン誘導体を含む抗体薬物複合体
JP2022519293A5 (https=)
JP6953435B2 (ja) 二量体化合物
KR20220117305A (ko) 인간 il-13에 대한 결합 특이성을 가진 항체
WO2023238845A1 (ja) 加齢疾患の治療又は予防のための抗インテグリンα11抗体を含む医薬組成物
JP7432531B2 (ja) システイン残基を有するヘミアスタリン誘導体
WO2026092606A1 (zh) 带有连接系统的抗体药物偶联物
JP2025541366A (ja) 腫瘍壊死因子受容体アゴニスト性mb
WO2026085538A1 (en) Antibody drug conjugates
IL325400A (en) Anti-human CACNG1 antibody-drug conjugates and their uses